1. Home
  2. BDTX vs GDL Comparison

BDTX vs GDL Comparison

Compare BDTX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.36

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

N/A

Current Price

$8.23

Market Cap

90.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
GDL
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
90.1M
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
BDTX
GDL
Price
$1.36
$8.23
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $11.00
N/A
AVG Volume (30 Days)
★ 766.3K
10.5K
Earning Date
11-10-2026
01-01-0001
Dividend Yield
N/A
★ 6.02%
EPS Growth
★ 130.71
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$8.01
52 Week High
$3.97
$8.67

Technical Indicators

Market Signals
Indicator
BDTX
GDL
Relative Strength Index (RSI) 34.73 36.42
Support Level N/A $8.01
Resistance Level $1.94 $8.43
Average True Range (ATR) 0.14 0.07
MACD -0.04 -0.00
Stochastic Oscillator 0.84 0.00

Price Performance

Historical Comparison
BDTX
GDL

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

Share on Social Networks: